{"id":"NCT00509873","sponsor":"Allergan","briefTitle":"A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2007-08-01","resultsPosted":"2011-11-30","lastUpdate":"2011-11-30"},"enrollment":578,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Gatifloxacin 0.5% eye drops","otherNames":[]},{"type":"DRUG","name":"placebo eye drops","otherNames":[]}],"arms":[{"label":"Gatifloxacin 0.5% Eye Drops","type":"EXPERIMENTAL"},{"label":"Placebo Eye Drops","type":"PLACEBO_COMPARATOR"}],"summary":"The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis","primaryOutcome":{"measure":"Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6","timeFrame":"Day 6","effectByArm":[{"arm":"Gatifloxacin 0.5% Eye Drops","deltaMin":74.9,"sd":null},{"arm":"Placebo Eye Drops","deltaMin":65.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["25244402"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":288},"commonTop":["Conjunctivitis bacterial"]}}